drugset
drugset / Trial / NCT05028478

A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

NCT05028478 ↗

Phase 1/2 Unknown 164 enrolled Curon Biopharmaceutical (Australia) Co Pty Ltd Novotech (Australia) Pty Limited · collab
NaSingle-groupOpen-labelTreatment

Summary

The study is designed to evaluate the safety, tolerability, pharmacokinetic characteristics and anti-tumor activity of CN202 in adult subjects with locally advanced or metastatic solid tumor or hematologic malignancies

Timeline

Start
2021-10-22
Primary completion
2023-02-10
Completion
2023-10-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CN202 Unknown 1 mg/kg Intravenous
Subject CN202 Unknown 3 mg/kg Intravenous
Subject CN202 Unknown 10 mg/kg Intravenous
Subject CN202 Unknown 20 mg/kg Intravenous

Indications

hematopoietic and lymphoid cell neoplasm metastatic neoplasm